• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Atossa Therapeutics to Present at the Jefferies Global Healthcare Conference

    6/2/25 8:45:00 AM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATOS alert in real time by email

    SEATTLE, June 2, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced that Dr. Steven Quay, M.D., Ph.D., President and Chief Executive Officer, will present at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025 at 7:35 a.m. Eastern Time.

    ATOS) is a clinical-stage biopharmaceutical company dedicated to transforming breast cancer treatment through innovative science and patient-focused solutions. The company's lead product candidate, (Z)-endoxifen, is a highly potent SERM designed for use across the breast cancer spectrum, including prevention, neoadjuvant, adjuvant, and metastatic settings. (PRNewsfoto/Atossa Therapeutics Inc)" alt="Atossa Therapeutics, Inc. (NASDAQ:ATOS) is a clinical-stage biopharmaceutical company dedicated to transforming breast cancer treatment through innovative science and patient-focused solutions. The company's lead product candidate, (Z)-endoxifen, is a highly potent SERM designed for use across the breast cancer spectrum, including prevention, neoadjuvant, adjuvant, and metastatic settings. (PRNewsfoto/Atossa Therapeutics Inc)">

    A live webcast of the presentation can be accessed on the Investors section of the Atossa website under "Events and Presentations" at https://investors.atossatherapeutics.com/news-events/events-presentations. The webcast will be archived for 30 days.

    About Atossa Therapeutics

    Atossa Therapeutics, Inc. (NASDAQ:ATOS) is a clinical-stage biopharmaceutical company dedicated to transforming breast cancer treatment through innovative science and patient-focused solutions. The company's lead product candidate, (Z)-endoxifen, is a highly potent SERM designed for use across the breast cancer spectrum, including prevention, neoadjuvant, adjuvant, and metastatic settings. Atossa is committed to advancing its robust clinical research programs to improve patient outcomes while creating sustainable value for shareholders. For more information, visit atossatherapeutics.com.

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/atossa-therapeutics-to-present-at-the-jefferies-global-healthcare-conference-302470615.html

    SOURCE Atossa Therapeutics Inc

    Get the next $ATOS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATOS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ATOS
    SEC Filings

    View All

    SEC Form 8-K filed by Atossa Therapeutics Inc.

    8-K - ATOSSA THERAPEUTICS, INC. (0001488039) (Filer)

    2/20/26 4:22:08 PM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Atossa Therapeutics Inc.

    424B5 - ATOSSA THERAPEUTICS, INC. (0001488039) (Filer)

    2/20/26 4:16:05 PM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by Atossa Therapeutics Inc.

    424B3 - ATOSSA THERAPEUTICS, INC. (0001488039) (Filer)

    2/20/26 4:07:14 PM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATOS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Quay Steven C bought $9,887 worth of shares (11,239 units at $0.88), increasing direct ownership by 423% to 13,898 units (SEC Form 4)

    4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)

    5/22/25 6:27:25 PM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Remmel H. Lawrence bought $7,000 worth of shares (10,000 units at $0.70), increasing direct ownership by 3,891% to 10,257 units (SEC Form 4)

    4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)

    3/28/25 4:00:03 PM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Finn Jonathan bought $44,250 worth of shares (25,000 units at $1.77) (SEC Form 4)

    4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)

    4/11/24 4:05:09 PM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATOS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology

    VANCOUVER, British Columbia, March 19, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary — Big money is moving back into biotech. Institutional investors have been writing some of the largest checks in years, with major financing rounds already closing in the first months of 2026[1], a sign that capital is rotating toward clinical-stage companies with validated science. That capital is not spreading evenly: it is concentrating on precision medicine, where the global oncology precision medicine market is projected to reach $303 billion by 2035[2], growing at approximately 9% annually as targeted cancer treatments move from promising idea to standard care. The five companies in thi

    3/19/26 11:00:00 AM ET
    $ATOS
    $ONCY
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives

    Kathy Puyana Theall, M.D. and Adebola Giwa, M.D. bring deep expertise across oncology, rare diseases, and global clinical development to support advancement of Atossa's pipelineSEATTLE, March 19, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other rare diseases, today announces the engagement of Kathy Puyana Theall, M.D., as Medical Director - Breast Oncology, and Adebola Giwa, M.D., as Medical Director - Rare Diseases.  The addition of these two highly experienced physicians and clinical leaders meaningfully strengthens Atossa's ability to execute on its (Z)-endo

    3/19/26 8:00:00 AM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference

    Study Highlights Findings that (Z)-endoxifen Restores Muscle Performance and Lowers Damage Biomarkers in mdx5Cv Dystrophic MiceSEATTLE, March 12, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other rare disease indications with significant unmet need, presented an oral clinical trial update on (Z)-endoxifen at the MDA Clinical & Scientific Conference on March 11, 2026, in Orlando, FL. Presentation HighlightsThe mdx5Cv Dystrophic mouse model, a trusted

    3/12/26 8:00:00 AM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATOS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: President & CEO Quay Steven C was granted 331,674 shares, increasing direct ownership by 2,386% to 345,572 units (SEC Form 4)

    4/A - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)

    1/30/26 8:30:03 AM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Quay Steven C was granted 325,203 shares, increasing direct ownership by 2,340% to 339,101 units (SEC Form 4)

    4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)

    1/22/26 2:11:52 PM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Financial Officer Daniel Mark James

    4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)

    10/21/25 4:10:03 PM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATOS
    Financials

    Live finance-specific insights

    View All

    Atossa Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Corporate Update

    FDA Provides Positive Feedback, Clears Path for Atossa to File IND for (Z)-Endoxifen in Metastatic Breast Cancer; FDA Indicates No Additional Toxicity Studies Required Strong I-SPY2 Results Reinforce Efficacy of Atossa's Monotherapy at 3-weeks SEATTLE, Aug. 12, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced its financial results for the second quarter ended June 30, 2025 and provided an update on recent company developments. "Atos

    8/12/25 8:30:00 AM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update

    Announced strategic plan to advance (Z)-endoxifen for metastatic breast cancer indication  Enhanced (Z)-endoxifen intellectual property portfolio with three new U.S. patents, expanding IP portfolio to more than 200 patent claims related to (Z)-endoxifen Ended first quarter 2025 with $65.1 million in cash and cash equivalents and no debt SEATTLE, May 13, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced its financial results for the first quarter ended March 31, 2025 and provided an update on recent company developments.

    5/13/25 8:00:00 AM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update

    Ended 2024 with $71.1 million of cash and cash equivalents and no debt Conference Call and Webcast Scheduled for Tuesday, March 25, 2025, at 8:30 a.m. Eastern Time SEATTLE, March 25, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced its financial results for the full year ended December 31, 2024 and provided an update on recent company developments. Fourth Quarter and Early 2025 Highlights Strategic Decision to Pursue Metastatic Breast Cancer Indication: Atossa plans to advance its lead program, (Z)-endoxifen, to target metastatic bre

    3/25/25 8:00:00 AM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATOS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Atossa Therapeutics Inc.

    SC 13G/A - ATOSSA THERAPEUTICS, INC. (0001488039) (Subject)

    11/12/24 1:32:30 PM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Atossa Therapeutics Inc.

    SC 13G/A - ATOSSA THERAPEUTICS, INC. (0001488039) (Subject)

    11/4/24 11:27:58 AM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Atossa Therapeutics Inc. (Amendment)

    SC 13G/A - ATOSSA THERAPEUTICS, INC. (0001488039) (Subject)

    2/9/23 11:07:47 AM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATOS
    Leadership Updates

    Live Leadership Updates

    View All

    Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives

    Kathy Puyana Theall, M.D. and Adebola Giwa, M.D. bring deep expertise across oncology, rare diseases, and global clinical development to support advancement of Atossa's pipelineSEATTLE, March 19, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other rare diseases, today announces the engagement of Kathy Puyana Theall, M.D., as Medical Director - Breast Oncology, and Adebola Giwa, M.D., as Medical Director - Rare Diseases.  The addition of these two highly experienced physicians and clinical leaders meaningfully strengthens Atossa's ability to execute on its (Z)-endo

    3/19/26 8:00:00 AM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook

    SEATTLE, Feb. 11, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet need, today issued a letter to Shareholders from Steven Quay, M.D., Ph.D., Atossa Therapeutics President and Chief Executive Officer, providing an update on the Company's clinical programs and recent events. The full text of the letter follows: To our valued shareholders, In looking back on 2025, Atossa made meaningful progress advancing proprietary oral (Z)-en

    2/11/26 8:30:00 AM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atossa Appoints Mark Daniel, CPA, as Chief Financial Officer to Lead Finance, Systems, and Capital Strategy for Commercial Readiness

    25+ year life-sciences finance leader brings revenue-forecasting rigor, public-company controls, and capital-markets experience as Atossa prepares for commercial operations with (Z)-endoxifen SEATTLE, Oct. 14, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing new approaches in breast cancer treatment and prevention, announces the appointment of Mark Daniel, CPA (WA; inactive), as Chief Financial Officer. Mr. Daniel is a senior finance leader with more than 25 years of experience building the forecasting cadence, systems, and public-company discipline that support revenue scale in global life-science

    10/14/25 8:00:00 AM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care